Condition

Nasopharyngeal Cancinoma (NPC) clinical trials and research

• 23Clinical trials
• 6Countries

Newest Nasopharyngeal Cancinoma (NPC) clinical trials

All recruiting trials (23)

• Nanocrystalline Megestrol Acetate to Help Appetite During Chemoradiotherapy in Nasopharyngeal Carcinoma

  This phase 3 trial tests whether taking nanocrystalline megestrol acetate can help people with nasopharyngeal carcinoma who are receiving chemoradiotherapy to keep their appetite and weight better than placebo.

  Recruiting at 3 sites Phase 3 Sun Yat-sen University · Guangzhou, Guangdong and 2 other locations · NCT07796789

• Becotatug Vedotin plus Anti-PD-1 as maintenance for recurrent/metastatic NPC

  This phase 3 trial tests whether adding becotatug vedotin to an anti-PD-1 therapy as maintenance can help people with recurrent or metastatic nasopharyngeal cancer who have stable disease after initial treatment.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT07705243

• Intratumoral EDS01 plus toripalimab for recurrent or metastatic head and neck cancer

  This phase 1 study tests whether directly injecting a gene‑therapy endostatin product (EDS01) into a tumor, together with the PD-1 inhibitor toripalimab, is safe and shows early signs of activity in adults with recurrent or metastatic head and neck cancer after platinum therapy.

  Recruiting Phase 1 West China Hospital · Chengdu, China · NCT07625423

• Maintenance immunotherapy with deferred salvage radiotherapy after response to chemoimmunotherapy in recurrent nasopharyngeal cancer

  This study tests whether continuing immunotherapy and delaying salvage radiotherapy after an initial chemoimmunotherapy response can help people with unresectable recurrent nasopharyngeal cancer live longer and feel better.

  Recruiting Phase 2 Sun Yat-sen University · Fuzhou, Fujian and 3 other locations · NCT07528183

• Becotatug vedotin added to radiation and adjuvant therapy for locally advanced nasopharyngeal cancer with a poor response to induction chemo‑immunotherapy

  This will test whether adding becotatug vedotin during radiation and afterward helps people with locally advanced nasopharyngeal cancer who had a suboptimal response to induction chemotherapy combined with immunotherapy.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07496190

• IMRT-only treatment for stage IB nasopharyngeal cancer without high-risk features

  This trial will test whether IMRT alone can control stage IB nasopharyngeal cancer without high-risk features in adults aged 18–70.

  Recruiting Fujian Cancer Hospital · Fuzhou, Fujian · NCT07376603

• Toripalimab with three platinum-based induction chemotherapies for locally advanced nasopharyngeal carcinoma

  This trial tests whether adding toripalimab to one of three different platinum-based induction chemotherapy regimens before standard concurrent chemoradiotherapy can improve outcomes for adults with locally advanced nasopharyngeal carcinoma.

  Recruiting at 4 sites Phase 2 Sun Yat-sen University · Dongguan, Guangdong and 3 other locations · NCT07362979

• Low-dose radiotherapy with toripalimab and chemotherapy for recurrent or metastatic nasopharyngeal cancer

  This will test whether adding low-dose radiotherapy to toripalimab plus gemcitabine‑cisplatin helps people with recurrent or metastatic nasopharyngeal cancer respond better while staying safe.

  Recruiting at 2 sites Phase 2 Sun Yat-sen University · Guangzhou, Guangdong and 1 other locations · NCT07325539

• Houyanqing oral liquid to prevent and treat radiation mouth sores in nasopharyngeal cancer

  This phase 3 trial will test whether adding Houyanqing oral liquid to standard care can prevent or lessen radiation-caused mouth sores in adults receiving radiotherapy for nasopharyngeal cancer.

  Recruiting at 16 sites Phase 3 Sun Yat-sen University · Beijing, Beijing Municipality and 15 other locations · NCT07311772

• Immuno-radiomic profiling for nasopharyngeal cancer treated with proton or photon chemoradiotherapy

  We will test if combining imaging-based radiomic features with immune markers can help predict treatment response, side effects, and long-term outcomes for adults with stage I–III nasopharyngeal cancer receiving proton or photon chemoradiotherapy.

  Recruiting Chang Gung Memorial Hospital · Taoyuan City, Taiwan · NCT07232680

• Adaptive immunotherapy for nasopharyngeal carcinoma

  This trial will test whether, after induction chemoimmunotherapy, low‑risk patients with undetectable EBV‑DNA can be safely treated with radiotherapy alone instead of concurrent chemoradiotherapy, and whether adding capecitabine to adjuvant immunotherapy improves outcomes for high‑risk patients with detectable EBV‑DNA

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT07154069

• Tislelizumab plus capecitabine for nasopharyngeal cancer with leftover EBV DNA after radiation

  This will test whether adding the immunotherapy tislelizumab to the oral chemotherapy capecitabine helps people with nasopharyngeal cancer who still have detectable EBV DNA after radiotherapy.

  Recruiting Phase 2 Fudan University · Shanghai, China · NCT07067268

• Improving TNM-10 staging for nasopharyngeal cancer worldwide

  This project will collect data from people with nasopharyngeal cancer treated in 2025–2026 to see if updating the TNM-10 anatomical staging and adding blood and molecular markers can better predict outcomes.

  Recruiting The University of Hong Kong-Shenzhen Hospital · Shenzhen, Guangdong · NCT07013461

• Comparing reduced dose and standard dose radiotherapy for early stage nasopharyngeal carcinoma

  This study is testing if a lower dose of radiotherapy is just as effective as the standard dose for patients with early stage nasopharyngeal carcinoma who have responded well to initial treatment.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT06912698

• Comparing different radiation therapies for nasopharyngeal carcinoma

  This study is testing whether a new combination of proton and carbon ion radiation therapy is just as effective and safe as a different combination of photon and carbon ion radiation therapy for people newly diagnosed with nasopharyngeal carcinoma.

  Recruiting Phase 3 Shanghai Proton and Heavy Ion Center · Shanghai, Shanghai Municipality · NCT06846450

• AI model predicts distant metastasis in nasopharyngeal cancer

  This study is testing a new AI tool to see if it can help doctors predict which patients with nasopharyngeal cancer are at high risk for spreading the disease, so they can get the right scans and avoid unnecessary ones.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong and 1 other locations · NCT06831357

• AI model for diagnosing lymph node metastasis in nasopharyngeal carcinoma

  This study is testing a new AI tool that helps doctors diagnose if nasopharyngeal carcinoma has spread to lymph nodes by looking at MRI images before and after chemotherapy.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT06829147

• Combining EGFR antibody, PD-1 inhibitor, and chemotherapy for advanced nasopharyngeal carcinoma

  This study tests a new combination of treatments using an EGFR antibody, a PD-1 inhibitor, and chemotherapy to see if it helps people with advanced nasopharyngeal carcinoma feel better compared to standard options.

  Recruiting Phase 1/2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06802835

• Combining low-dose radiotherapy with chemoimmunotherapy for nasopharyngeal carcinoma with liver metastasis

  This study is testing whether adding low-dose radiation to chemotherapy and immunotherapy can help people with nasopharyngeal cancer that has spread to the liver feel better and improve their treatment results.

  Recruiting at 8 sites Phase 2 Hunan Cancer Hospital · Changsha, Hunan and 7 other locations · NCT06788002

• Combination of QL1706 and Chemoradiotherapy for Advanced Nasopharyngeal Cancer

  This study is testing if adding a new drug called QL1706 to standard chemotherapy and radiation can help people with advanced nasopharyngeal cancer live better and longer.

  Recruiting Phase 3 Sun Yat-sen University · Fuzhou, Fujian and 18 other locations · NCT06749899

• Focused radiation plus nimotuzumab followed by tislelizumab for oligoprogressive recurrent or metastatic nasopharyngeal cancer after prior immunotherapy

  This trial will try focused stereotactic radiation together with the antibody nimotuzumab, followed by the PD‑1 drug tislelizumab, in people whose recurrent or metastatic nasopharyngeal cancer has progressed at 1–5 spots after prior anti–PD‑1 treatment.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian and 1 other locations · NCT06676722

• Comparing two chemotherapy regimens with Camrelizumab for advanced nasopharyngeal carcinoma

  This study is testing whether two different chemotherapy treatments combined with the immunotherapy drug Camrelizumab can help people with advanced nasopharyngeal cancer live longer and feel better.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT06669611

• Testing a new antibody treatment for advanced squamous cell cancers

  This study is testing a new antibody treatment combined with chemotherapy for people with advanced squamous cell cancers that haven't responded to standard therapies.

  Recruiting at 17 sites Phase 1/2 Hummingbird Bioscience · Sydney, New South Wales and 19 other locations · NCT05910827

Related topics

Quick answers

How many Nasopharyngeal Cancinoma (NPC) clinical trials are recruiting right now?

23, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 6 countries. The most sites are in China (21 trials), Taiwan (2 trials), Australia (1 trial), Moldova (1 trial), Singapore (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 8, Phase 2: 7, Phase 1/2: 2, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →